BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects

Jurjen J. Luykx; Marco P.M. Boks; Elemi J. Breetvelt; Maartje F. Aukes; Eric Strengman; Eleonora da Pozzo; Liliana Dell'osso; Donatella Marazziti; Annelies van Leeuwen; Annabel Vreeker; Lucija Abramovic; Claudia Martini; Mattijs E. Numans; René S. Kahn; Roel A. Ophoff

doi:10.1016/j.pnpbp.2012.12.017

BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects

Jurjen J. Luykx^*, Marco P.M. Boks, Elemi J. Breetvelt, Maartje F. Aukes, Eric Strengman, Eleonora da Pozzo, Liliana Dell'osso, Donatella Marazziti, Annelies van Leeuwen, Annabel Vreeker, Lucija Abramovic, Claudia Martini, Mattijs E. Numans, René S. Kahn, Roel A. Ophoff

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

7 Citations (Scopus)

Abstract

A putative pathway by which the BDNF Val66Met polymorphism (rs6265) leads to aberrant phenotypes is its influence on plasma BDNF. Research into the impact of rs6265 on plasma BDNF has given rise to conflicting results. Moreover, most such studies have compared Met-carriers with Val-homozygous subjects. We therefore genotyped subjects from a population-based cohort (the Utrecht Health Project, N = 2743) and assessed whether plasma BDNF differs between rs6265 homozygous groups. We maximized the number of Met-homozygous subjects in whom we measured plasma BDNF, resulting in plasma BDNF being available for 19 Met-homozygous and 42 matched Val-homozygous subjects. Mean concentrations (S.D.) were 1963.1 (750.1) and 2133.2. pg/ml (1164.3) for the Val/Val and Met/Met groups, respectively. Using ANOVA, no differences in plasma BDNF between the two groups were detected. In conclusion, these results add to a growing body of evidence indicating that allelic variation at rs6265 does not have medium to large effects on plasma BDNF concentrations.

Original language	English
Pages (from-to)	185-187
Number of pages	3
Journal	Progress in Neuro-Psychopharmacology and Biological Psychiatry
Volume	43
DOIs	https://doi.org/10.1016/j.pnpbp.2012.12.017
Publication status	Published - 3 Jun 2013

Keywords

BDNF
Homozygosity
Plasma
Plasma BDNF
Rs6265

Access to Document

10.1016/j.pnpbp.2012.12.017

Cite this

Luykx, J. J., Boks, M. P. M., Breetvelt, E. J., Aukes, M. F., Strengman, E., da Pozzo, E., Dell'osso, L., Marazziti, D., van Leeuwen, A., Vreeker, A., Abramovic, L., Martini, C., Numans, M. E., Kahn, R. S., & Ophoff, R. A. (2013). BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 43, 185-187. https://doi.org/10.1016/j.pnpbp.2012.12.017

@article{9f29aa37068a47a7b15916790b2b1a5f,

title = "BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects",

abstract = "A putative pathway by which the BDNF Val66Met polymorphism (rs6265) leads to aberrant phenotypes is its influence on plasma BDNF. Research into the impact of rs6265 on plasma BDNF has given rise to conflicting results. Moreover, most such studies have compared Met-carriers with Val-homozygous subjects. We therefore genotyped subjects from a population-based cohort (the Utrecht Health Project, N = 2743) and assessed whether plasma BDNF differs between rs6265 homozygous groups. We maximized the number of Met-homozygous subjects in whom we measured plasma BDNF, resulting in plasma BDNF being available for 19 Met-homozygous and 42 matched Val-homozygous subjects. Mean concentrations (S.D.) were 1963.1 (750.1) and 2133.2. pg/ml (1164.3) for the Val/Val and Met/Met groups, respectively. Using ANOVA, no differences in plasma BDNF between the two groups were detected. In conclusion, these results add to a growing body of evidence indicating that allelic variation at rs6265 does not have medium to large effects on plasma BDNF concentrations.",

keywords = "BDNF, Homozygosity, Plasma, Plasma BDNF, Rs6265",

author = "Luykx, {Jurjen J.} and Boks, {Marco P.M.} and Breetvelt, {Elemi J.} and Aukes, {Maartje F.} and Eric Strengman and {da Pozzo}, Eleonora and Liliana Dell'osso and Donatella Marazziti and {van Leeuwen}, Annelies and Annabel Vreeker and Lucija Abramovic and Claudia Martini and Numans, {Mattijs E.} and Kahn, {Ren{\'e} S.} and Ophoff, {Roel A.}",

year = "2013",

month = jun,

day = "3",

doi = "10.1016/j.pnpbp.2012.12.017",

language = "English",

volume = "43",

pages = "185--187",

journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",

issn = "0278-5846",

publisher = "Elsevier",

}

Luykx, JJ , Boks, MPM, Breetvelt, EJ, Aukes, MF, Strengman, E, da Pozzo, E, Dell'osso, L, Marazziti, D, van Leeuwen, A, Vreeker, A, Abramovic, L, Martini, C, Numans, ME, Kahn, RS & Ophoff, RA 2013, 'BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 43, pp. 185-187. https://doi.org/10.1016/j.pnpbp.2012.12.017

TY - JOUR

T1 - BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects

AU - Luykx, Jurjen J.

AU - Boks, Marco P.M.

AU - Breetvelt, Elemi J.

AU - Aukes, Maartje F.

AU - Strengman, Eric

AU - da Pozzo, Eleonora

AU - Dell'osso, Liliana

AU - Marazziti, Donatella

AU - van Leeuwen, Annelies

AU - Vreeker, Annabel

AU - Abramovic, Lucija

AU - Martini, Claudia

AU - Numans, Mattijs E.

AU - Kahn, René S.

AU - Ophoff, Roel A.

PY - 2013/6/3

Y1 - 2013/6/3

N2 - A putative pathway by which the BDNF Val66Met polymorphism (rs6265) leads to aberrant phenotypes is its influence on plasma BDNF. Research into the impact of rs6265 on plasma BDNF has given rise to conflicting results. Moreover, most such studies have compared Met-carriers with Val-homozygous subjects. We therefore genotyped subjects from a population-based cohort (the Utrecht Health Project, N = 2743) and assessed whether plasma BDNF differs between rs6265 homozygous groups. We maximized the number of Met-homozygous subjects in whom we measured plasma BDNF, resulting in plasma BDNF being available for 19 Met-homozygous and 42 matched Val-homozygous subjects. Mean concentrations (S.D.) were 1963.1 (750.1) and 2133.2. pg/ml (1164.3) for the Val/Val and Met/Met groups, respectively. Using ANOVA, no differences in plasma BDNF between the two groups were detected. In conclusion, these results add to a growing body of evidence indicating that allelic variation at rs6265 does not have medium to large effects on plasma BDNF concentrations.

AB - A putative pathway by which the BDNF Val66Met polymorphism (rs6265) leads to aberrant phenotypes is its influence on plasma BDNF. Research into the impact of rs6265 on plasma BDNF has given rise to conflicting results. Moreover, most such studies have compared Met-carriers with Val-homozygous subjects. We therefore genotyped subjects from a population-based cohort (the Utrecht Health Project, N = 2743) and assessed whether plasma BDNF differs between rs6265 homozygous groups. We maximized the number of Met-homozygous subjects in whom we measured plasma BDNF, resulting in plasma BDNF being available for 19 Met-homozygous and 42 matched Val-homozygous subjects. Mean concentrations (S.D.) were 1963.1 (750.1) and 2133.2. pg/ml (1164.3) for the Val/Val and Met/Met groups, respectively. Using ANOVA, no differences in plasma BDNF between the two groups were detected. In conclusion, these results add to a growing body of evidence indicating that allelic variation at rs6265 does not have medium to large effects on plasma BDNF concentrations.

KW - BDNF

KW - Homozygosity

KW - Plasma

KW - Plasma BDNF

KW - Rs6265

UR - http://www.scopus.com/inward/record.url?scp=84872872607&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2012.12.017

DO - 10.1016/j.pnpbp.2012.12.017

M3 - Article

C2 - 23269345

AN - SCOPUS:84872872607

SN - 0278-5846

VL - 43

SP - 185

EP - 187

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

ER -

BDNF Val66Met homozygosity does not influence plasma BDNF levels in healthy human subjects

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this